📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-11 16:12
343 analysed today
343
Today
133,232
All-time analysed
40,094
Positive
6,279
Negative
79,048
Neutral
7,743
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
25 announcements match the current filters (relevance ≥ 5).
27% Revenue Growth in Q1 FY27; Specialty Ingredient Sales Surpass Full Year FY26 Levels
Sudeep Pharma reported a strong 27% YoY consolidated revenue growth for Q1 FY27, driven by a 31% surge in the Pharma, Food, and Nutrition segment. A standout performance was seen in the Absorbis Bisglycinates portfolio, where Q1 sales alone exceeded the total sales achieved in the entire previous financial year. Despite a 50% spike in phosphoric acid costs, management is maintaining an EBITDA margin target of 37-38% through price pass-throughs. The company is also progressing on its battery materials facility (25,000 MT) with a strict non-China supply chain strategy to ensure US market compliance.
Confidence: HIGH
What changedThe company has successfully transitioned its specialty ingredient portfolio to a high-growth phase and is shifting from a distributor-led to a direct-to-customer model in Europe.
Why it mattersThe massive growth in specialty ingredients (Absorbis) indicates a successful move up the value chain, while the battery materials strategy provides a long-term structural growth lever independent of traditional pharma cycles.
Revenue Growth (YoY): 27%Pharma/Nutrition Segment Growth: 31%Phosphoric Acid Price Hike: 50%Target EBITDA Margin: 37-38%Total Planned Capacity: 123,446 MTLong-term Working Capital Target: 150 days
📅 Short termThe stock may react positively to the significant outperformance in the specialty segment and the management's confidence in maintaining high margins despite cost pressures.
📈 Long termThe expansion into battery materials (targeting 100-200 KTPA eventually) and the doubling of core capacity position the company for a significant scale-up over the next 2-3 years.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Raw material price volatility (Phosphoric Acid)
- Geopolitical logistics disruptions affecting European subsidiaries
- Execution risk in the new battery materials segment
Key Highlights
Consolidated revenue grew 27% YoY, led by 31% growth in the Pharma and Nutrition segment.
Absorbis Bisglycinates Q1 sales surpassed the total sales achieved during the entire previous financial year.
Phosphoric acid prices increased by approximately 50% during the quarter, with price pass-throughs expected to offset impact in Q2.
Maintained EBITDA margin guidance of 37-38% despite raw material and logistics headwinds.
Greenfield expansion in Dahej to add 51,200 MT, bringing total capacity to 123,446 MT.
👀 What to Watch
Watch for the margin trajectory in Q2 FY27 to confirm the successful pass-through of raw material costs and monitor the execution timeline of the Dahej facility which nearly doubles existing capacity.
27% Revenue Growth in Q1FY27; Rs 300 Cr Battery Material Project on Track for March 2027
Sudeep Pharma reported a strong Q1FY27 with revenue growing 27% YoY to Rs 158.3 cr and PAT increasing 30% to Rs 40.6 cr. The company is aggressively diversifying into the EV battery materials segment (SAM project) with a Rs 300 cr investment, targeting 25,000 MT capacity by March 2027. Despite headwinds in the European market (NSS subsidiary) and elevated logistics costs, EBITDA margins remained resilient at 34.7%. The company also signed two additional MoUs with South Korean manufacturers for battery-grade iron phosphate.
Confidence: HIGH
What changedThe company has transitioned from reporting historical performance to providing concrete timelines and MoU progress for its major diversification into EV battery materials.
Why it mattersThe entry into battery-grade iron phosphate (25,000 MT) represents a significant high-growth pivot from traditional pharma excipients, with the project cost representing nearly 47% of FY26 revenue.
Q1FY27 Revenue: Rs 158.3 crSAM Project Cost: Rs 300 crSAM Project vs FY26 Revenue: 46.7%Total Core Capacity Target: 123,446 MTEBITDA Margin: 34.7%
📅 Short termThe strong Q1 earnings and progress on the battery material MoUs are likely to support positive sentiment in the coming weeks.
📈 Long termThe structural shift towards becoming a non-Chinese supplier for the EV battery supply chain, combined with a 70% increase in core capacity, provides a multi-year growth runway.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Subdued demand in European markets (NSS)
- Execution risk for the Rs 300 cr greenfield battery project
- Exposure to global logistics and gas supply constraints
Key Highlights
Revenue from operations grew 27% YoY to Rs 158.3 cr in Q1FY27.
Profit After Tax (PAT) increased 30% YoY to Rs 40.6 cr with a 25.6% margin.
Battery Materials project (SAM) Phase 1 on track for March 2027 commissioning with a Rs 300 cr investment.
Signed 2 additional MoUs with leading South Korean CAM manufacturers for battery materials.
Greenfield expansion in Dahej to add 51,200 MT, targeting a total core capacity of 123,446 MT.
👀 What to Watch
Monitor the execution timeline of the SAM battery materials project scheduled for March 2027 and the conversion of MoUs into firm off-take contracts. Watch for demand recovery in the European market which currently remains subdued due to high energy costs.
27% Revenue Growth in Q1 FY27; ₹300 Cr Battery Material Project on Track for March 2027
Sudeep Pharma reported a strong Q1 FY27 with revenue growing 27% YoY to ₹158.3 Cr and PAT increasing 30% to ₹40.6 Cr. The company is aggressively diversifying into the EV supply chain via its Sudeep Advanced Materials (SAM) project, a ₹300 Cr investment in Dahej targeting 25,000 MT of battery-grade iron phosphate. While EBITDA margins saw a slight compression of 40 bps to 34.7%, the company maintained a healthy PAT margin of 25.6%. A massive greenfield expansion is also underway to increase core pharma/nutrition capacity by 51,200 MT, representing a ~70% increase over current levels.
Confidence: HIGH
What changedThe company has provided a concrete update on its Q1 FY27 performance and the progress of its ₹300 Cr diversification into battery materials, including the signing of new strategic MoUs.
Why it mattersThe pivot into battery-grade iron phosphate for EVs represents a significant structural shift that could re-rate the company from a pure-play pharma excipient manufacturer to a high-growth advanced materials supplier.
Q1 FY27 Revenue Growth: 27%SAM Project Cost: ₹300 CrSAM Project vs FY26 Revenue: 46.7%Greenfield Capacity Addition: 51,200 MTTotal Battery MoUs: 8
📅 Short termPositive sentiment expected due to robust double-digit growth in both top-line and bottom-line despite global supply chain headwinds.
📈 Long termThe successful commissioning of the 25,000 MT battery material plant and the 51,200 MT pharma expansion could significantly scale the business by FY28.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution risk for the ₹300 Cr SAM project
- Subdued demand in the European market impacting NSS integration
- High logistics costs and container shortages
Key Highlights
Revenue from operations grew 27% YoY to ₹158.3 Cr in Q1 FY27
PAT increased 30% YoY to ₹40.6 Cr with a margin of 25.6%
₹300 Cr investment in Battery Materials (SAM) project on track for March 2027 commissioning
Total manufacturing capacity to expand from 72,246 MT to 123,446 MT via Greenfield project
Signed 2 additional MoUs with South Korean manufacturers, totaling 8 MoUs for the battery segment
👀 What to Watch
Monitor the execution timeline of the Dahej Greenfield facility and the SAM project commissioning by March 2027. Investors should also track the conversion of the 8 MoUs into firm off-take agreements and the recovery of demand in the European market (NSS subsidiary).
29.8% YoY PAT Growth in Q1 FY27; Revenue Reaches ₹158.27 Cr
Sudeep Pharma reported a consolidated revenue of ₹158.27 cr for Q1 FY27, marking a 26.7% increase over Q1 FY26. Net profit grew 29.8% YoY to ₹40.59 cr, although it declined 16.4% sequentially from Q4 FY26. The company maintains a significant cash buffer with ₹75.46 cr of unutilized IPO proceeds currently held in bank deposits, intended for machinery procurement. Operational performance remains steady with an EPS of ₹3.59, up from ₹2.84 in the year-ago period.
Confidence: HIGH
What changedThe company has reported its Q1 FY27 financial results, showing strong year-on-year growth in both top-line and bottom-line figures, while maintaining a large unspent IPO capital pool.
Why it mattersThe results validate the company's 26% expected growth trajectory and its ability to maintain profitability despite a sequential dip in revenue. The high level of unutilized IPO funds suggests a lag in capex execution which needs to be monitored.
Revenue (Q1 FY27): ₹158.27 crNet Profit (Q1 FY27): ₹40.59 crYoY Revenue Growth: 26.7%Unutilized IPO Proceeds: ₹75.46 crBasic EPS: ₹3.59
📅 Short termThe stock may see positive sentiment due to strong YoY growth, though the sequential (QoQ) decline in revenue and profit might lead to some consolidation.
📈 Long termThe long-term outlook depends on the successful integration of the NSS acquisition and the operationalization of the 25,000 MT battery materials facility and the 51,200 MT Dahej expansion.
⚠ Risk flags
- Slow utilization of IPO proceeds for planned machinery procurement
- High client concentration with top 10 customers contributing 42% of revenue
- Sequential decline in revenue and profit compared to Q4 FY26
Key Highlights
Consolidated Revenue from operations increased 26.7% YoY to ₹158.27 cr from ₹124.92 cr.
Net Profit for the quarter rose to ₹40.59 cr, a 29.8% increase compared to ₹31.27 cr in Q1 FY26.
Unutilized IPO proceeds stand at ₹75.46 cr as of June 30, 2026, primarily earmarked for Nandesari facility machinery.
Employee benefit expenses increased to ₹14.34 cr from ₹12.24 cr in the corresponding quarter last year.
Total comprehensive income for the period stood at ₹40.53 cr after accounting for foreign operation translation losses.
👀 What to Watch
Investors should monitor the deployment timeline of the ₹75.46 cr unutilized IPO proceeds into machinery, which is critical for capacity ramp-up. Additionally, track the progress of the Dahej greenfield expansion and battery materials facility, which are expected to drive long-term growth by FY27.
₹642.3 Cr Revenue in FY26; 25,000 MT Battery Material Plant on Track for 2027
Sudeep Pharma reported a strong FY 2025-26 with revenue of ₹642.3 crore and a PAT margin of 27.1%. The core Pharma and Nutrition segment grew 10% to ₹362 crore, though growth was limited by near-optimal capacity utilization. A major strategic shift is underway with a 25,000 MT battery material facility in Dahej targeted for April 2027, which has already secured 700 MT in initial orders. Shareholders ratified the 2025 ESOP scheme and approved the dividend for the fiscal year.
Confidence: HIGH
What changedThe company has formalized its entry into the battery materials segment with a clear commissioning date and initial orders, while confirming strong FY26 financial performance.
Why it mattersThe diversification into the EV battery ecosystem (25,000 MT capacity) provides a high-growth vertical that complements the stable but capacity-constrained pharma excipients business.
FY26 Revenue: ₹642.3 crorePAT Margin: 27.1%Battery Material Capacity: 25,000 MTInitial Battery Orders: 700 MTExport Revenue Share: 60%
📅 Short termThe stock may see positive sentiment following the confirmation of strong margins and concrete progress on the new battery materials segment.
📈 Long termThe successful ramp-up of the 25,000 MT battery material plant and the 51,200 MT Greenfield expansion could significantly scale the business by FY28.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution risk for the Greenfield Dahej facility
- Current capacity constraints in core segments
- Elevated working capital due to international inventory stocking
Key Highlights
Reported FY 2025-26 revenue of ₹642.3 crore with a robust EBITDA margin of 34.6%.
Advanced battery material facility at Dahej (25,000 MT capacity) is on track for April 2027 commissioning.
Secured initial commercial orders of approximately 700 metric tonnes for battery-grade materials ahead of plant completion.
Pharma, Food, and Nutrition segment revenue grew 10% to ₹362 crore, contributing 56% of total revenue.
Exports remained a core strength, accounting for approximately 60% of the total revenue mix.
👀 What to Watch
Investors should monitor the execution timeline of the Dahej battery material facility (April 2027) and the customer qualification progress at the new Nandesari facility to address current capacity constraints.
₹1.50 Final Dividend: Sudeep Pharma Sets July 23, 2026, as Record Date
Sudeep Pharma Limited has fixed July 23, 2026, as the record date for its final dividend of ₹1.50 per equity share for the financial year 2025-26. This dividend is based on a face value of ₹1 per share, representing a 150% payout. The distribution is subject to shareholder approval at the 37th Annual General Meeting (AGM) scheduled for August 4, 2026. At the current market price of ₹828.9, the dividend yield stands at approximately 0.18%.
Confidence: HIGH
What changedThe company has officially set the timeline (record date and AGM date) for the payment of its previously recommended final dividend for FY 2025-26.
Why it mattersWhile the dividend yield is relatively low at 0.18%, the announcement confirms the company's intent to share profits with investors following a strong Sep 2025 quarter where it reported a net profit of ₹46.78 cr.
Dividend per share: ₹1.50Face Value: ₹1Record Date: 23-Jul-2026Dividend Yield: ~0.18%AGM Date: 04-Aug-2026
📅 Short termThe stock may experience minor price adjustments around the ex-dividend date, though the low yield suggests the impact will be minimal.
📈 Long termLimited. This is a routine corporate action; the long-term value remains tied to the company's 51,200 MT Greenfield expansion in Dahej and its entry into the battery materials segment.
Key Highlights
Final dividend of ₹1.50 per equity share recommended for FY 2025-26
Record date for determining shareholder entitlement is July 23, 2026
37th Annual General Meeting (AGM) to be held on August 4, 2026
Dividend payout is based on a face value of ₹1 per share
Payment will be processed within the stipulated time period post-AGM approval
👀 What to Watch
Investors interested in the dividend must hold the shares in their demat account by the record date of July 23, 2026. Monitor the AGM outcome on August 4, 2026, for formal approval of the payout.
₹1.50 Dividend and FY26 Revenue of ₹338.5 Cr Announced in 37th AGM Notice
Sudeep Pharma has issued its 37th AGM notice for August 4, 2026, proposing a dividend of ₹1.50 per share (150% payout). The company reported FY 2025-26 revenue of ₹338.51 cr, a 5.1% decline from the previous year, though Profit After Tax (PAT) grew 12.3% to ₹107.58 cr. Key agenda items include the re-appointment of Whole Time Director Mr. Ajay Kandelkar with a revised remuneration of ₹114.97 lakhs. Investors should note the high PAT margin of 31.8% despite the slight revenue contraction.
Confidence: HIGH
What changedThe company has formalized its FY26 financial performance and dividend proposal, while seeking shareholder approval for management continuity and remuneration.
Why it mattersThe filing confirms the company's ability to grow profits despite a slight revenue dip, maintaining high margins in the specialized mineral-based excipients market.
Dividend per share: ₹1.50FY26 Revenue: ₹338.51 crFY26 PAT: ₹107.58 crPAT Margin: 31.8%Revenue Growth (YoY): -5.1%
📅 Short termThe stock may see neutral to slightly positive movement leading up to the July 28, 2026 cut-off date for dividend eligibility.
📈 Long termStructural growth depends on the successful integration of the NSS (Ireland) acquisition and the commissioning of the 25,000 MT battery material facility in Dahej.
⚠ Risk flags
- Client concentration (top 10 customers contribute 42% of revenue)
- Raw material price volatility affecting annual contracts
Key Highlights
Proposed dividend of ₹1.50 per equity share of face value ₹1 (150% payout ratio).
FY 2025-26 Revenue stood at ₹338.51 cr compared to ₹356.73 cr in FY 2024-25.
Profit After Tax (PAT) increased to ₹107.58 cr from ₹95.75 cr in the previous year.
Proposed remuneration for Whole Time Director Mr. Ajay Kandelkar is ₹114.97 lakhs p.a.
Company maintains a strong PAT margin of 31.8% for the financial year ended March 31, 2026.
👀 What to Watch
Monitor the approval of the dividend and the progress of the Greenfield expansion in Dahej, which is expected to add 51,200 MT of capacity and drive future revenue growth.
Sudeep Pharma Appoints CA Milin Mehta as Non-Executive Non-Independent Director
Sudeep Pharma Limited has appointed Mr. Milin Mehta as an Additional Director in the Non-Executive Non-Independent category effective June 26, 2026. Mr. Mehta is a seasoned professional with over 30 years of experience as a Chartered Accountant and Law Graduate, currently serving as the Managing Partner at K C Mehta & Co LLP. His expertise spans international tax, transfer pricing, and transaction advisory services, which is expected to strengthen the board's strategic and regulatory oversight. The appointment is subject to shareholder approval and follows a board meeting held on the same day.
Key Highlights
Appointment of Mr. Milin Mehta as Additional Director effective June 26, 2026
Mr. Mehta brings over 30 years of experience in accounting, law, and strategic leadership
He has previously contributed to national policy initiatives including Income Computation and Disclosure Standards (ICDS)
The board meeting concluded within 35 minutes, starting at 03:30 p.m. and ending at 04:05 p.m.
👀 What to Watch
Investors should view this as a positive step towards strengthening corporate governance and strategic advisory. No immediate action is required as this is a routine board-level appointment of a highly qualified professional.
Sudeep Pharma Appoints Mr. Milin Mehta as Non-Executive Non-Independent Director
Sudeep Pharma Limited has appointed Mr. Milin Mehta as an Additional Director in the Non-Executive Non-Independent category, effective June 26, 2026. Mr. Mehta is a seasoned Chartered Accountant and Law Graduate with over 30 years of experience in tax, regulatory, and strategic advisory. He is the Managing Partner of K C Mehta & Co LLP and has previously contributed to national policy initiatives like the Income Computation and Disclosure Standards (ICDS). His extensive background in corporate governance and finance is expected to strengthen the company's board oversight.
Key Highlights
Appointment of Mr. Milin Mehta as Additional Director effective from June 26, 2026.
Mr. Mehta brings over 30 years of professional experience in accounting, legal, and strategic leadership.
He has served as an advisor to the Government of India and CBDT on key tax policy initiatives.
The appointment is subject to shareholder approval and is liable to retire by rotation.
👀 What to Watch
Investors should view this appointment as a positive move to enhance the board's financial and regulatory expertise. No immediate portfolio changes are necessary based on this administrative update.
Sudeep Pharma FY26 Revenue Growth Driven by 62% Surge in Specialty Ingredients
Sudeep Pharma reported a transformational FY26, with its specialty ingredients vertical growing 62% to INR 280 crores, now accounting for 44% of total revenue. The company successfully integrated its Irish acquisition (NSS) and is diversifying into the battery materials sector with a 25,000 MTPA project in Dahej scheduled for April 2027. Despite global raw material inflation, the company maintained margins through effective price pass-throughs and secured 51 new customer approvals during the year.
Key Highlights
Specialty ingredients revenue grew 62% YoY from INR 172 Cr to INR 280 Cr
Secured 51 new customer approvals in FY26 across global markets
Battery materials project (SAM) on track for Phase 1 commissioning of 25,000 MTPA by April 2027
Engaging with 42 global customers for battery-grade iron phosphate, with 6 already completing commercial validation
Pharma food and nutrition vertical grew 10% despite phosphoric acid price volatility
👀 What to Watch
Investors should monitor the commissioning of the Dahej battery materials plant and the ramp-up of the new greenfield facility as primary growth catalysts. The strategic shift toward high-margin specialty ingredients and the 'China Plus One' opportunity in battery materials provide a strong long-term outlook.
Sudeep Pharma FY26 Revenue Jumps 28% to ₹642.3 Cr; Battery Materials Plant Construction Underway
Sudeep Pharma reported a robust performance for FY26, with revenue growing 28% YoY to ₹642.3 crore and PAT rising 26% to ₹174.3 crore. The year was marked by the successful integration of Nutrition Supplies Services (NSS) and the groundbreaking of a new battery materials facility in Dahej. While EBITDA margins compressed slightly to 34.6% due to rising raw material costs and gas supply issues, the company secured significant initial orders for its battery-grade iron phosphate. Working capital days increased to 213, primarily due to strategic inventory buildup and geopolitical supply chain disruptions.
Key Highlights
Annual revenue reached a record ₹642.3 crore in FY26, driven by a 28% YoY growth and NSS integration.
Groundbreaking completed for the Dahej Battery Materials Plant with an initial Phase 1 capacity of 25,000 MT.
Secured a 500 MT purchase order for battery materials from a leading listed Indian player and qualification orders from Korea.
Acquired an 85% stake in Nutrition Supplies Services (NSS), significantly expanding European market reach.
Working capital cycle lengthened to 213 days from 184 days YoY due to US/Europe warehousing and West Asia conflict disruptions.
👀 What to Watch
Investors should focus on the execution of the Dahej greenfield project and the company's transition into the EV supply chain. While working capital is currently stretched, the strong growth in the core pharma/nutrition business and high ROCE of 22.5% provide a solid foundation.
Sudeep Pharma Recommends Final Dividend of Rs 1.50 (150%) for FY 2025-26
Sudeep Pharma Limited's Board of Directors has recommended a final dividend of Rs. 1.50 per equity share, representing a 150% payout on the face value of Rs. 1. This recommendation follows the approval of the company's audited standalone and consolidated financial results for the fiscal year ended March 31, 2026. The company also announced the appointment of new Cost and Secretarial auditors for the upcoming periods. The dividend remains subject to shareholder approval at the forthcoming Annual General Meeting.
Key Highlights
Recommended a final dividend of Rs. 1.50 per equity share (150% of face value) for FY 2025-26.
Approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.
Appointed M/s H M Mehta & Associates as Secretarial Auditor for a five-year term until FY 2030-31.
Appointed M/s Chetan Gandhi & Associates as Cost Auditor for the financial year 2026-27.
Statutory auditors B S R and Co issued an unmodified audit report on the consolidated financial results.
👀 What to Watch
Investors should track the upcoming Annual General Meeting (AGM) and the subsequent record date to qualify for the Rs. 1.50 dividend. The 150% dividend payout suggests a stable financial position and a shareholder-friendly management approach.
Sudeep Pharma Recommends ₹1.50 Final Dividend and Approves FY26 Financial Results
Sudeep Pharma's Board has approved the audited financial results for the fiscal year ending March 31, 2026. The company recommended a final dividend of ₹1.50 per share, representing a 150% payout on the face value of ₹1, subject to shareholder approval. Additionally, the board appointed new Cost and Secretarial Auditors to ensure regulatory compliance for the upcoming years. The independent auditor, BSR and Co, issued a clean report on the consolidated financial statements, confirming a true and fair view of the company's performance.
Key Highlights
Recommended a final dividend of ₹1.50 per equity share (150% of face value of ₹1)
Approved audited standalone and consolidated financial results for the year ended March 31, 2026
Appointed M/s H M Mehta & Associates as Secretarial Auditor for a 5-year term until FY 2030-31
Appointed M/s Chetan Gandhi & Associates as Cost Auditor for the financial year 2026-27
Statutory auditor BSR and Co provided an unqualified opinion on the consolidated financial results
👀 What to Watch
Investors should monitor the upcoming Annual General Meeting for dividend approval and review the detailed financial statements for growth trends. The 150% dividend payout indicates a healthy cash position and commitment to shareholder returns.
Sudeep Pharma Recommends ₹1.50 Final Dividend and Approves FY26 Financial Results
Sudeep Pharma Limited has approved its audited financial results for the fiscal year ended March 31, 2026. A key highlight for shareholders is the recommendation of a final dividend of ₹1.50 per equity share, representing 150% of the face value. The company also announced the appointment of new Cost and Secretarial Auditors, with the latter appointed for a long-term five-year tenure. These moves indicate a focus on both rewarding investors and maintaining robust corporate governance standards.
Key Highlights
Recommended a final dividend of ₹1.50 per equity share (150% of ₹1 face value) for FY 2025-26.
Approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.
Appointed M/s H M Mehta & Associates as Secretarial Auditor for a 5-year term from FY 2026-27 to 2030-31.
Appointed M/s Chetan Gandhi & Associates as Cost Auditor for the upcoming financial year 2026-27.
👀 What to Watch
Investors should monitor the upcoming Annual General Meeting for the final approval of the ₹1.50 dividend. The long-term appointment of auditors suggests a stable regulatory outlook for the company.
Sudeep Pharma Q3 FY26 Earnings Call: 20% Domestic Growth and Major Capacity Expansion
Sudeep Pharma reported a steady Q3 FY26 performance with 20% growth in the domestic market and strong traction in APAC and Europe. The company is strategically pivoting towards high-margin specialty ingredients and battery-grade iron phosphate, positioning itself as a key ex-China supplier. Significant capacity expansions are underway, including the 51,200 MTPA Nandesari facility due in March 2026 and the 25,000 MTPA Dahej battery materials plant slated for 2027. Management highlighted deepening relationships with global FMCG and baked goods leaders, providing long-term revenue visibility.
Key Highlights
Domestic market revenue grew by nearly 20% in Q3 FY26 supported by stable demand.
Nandesari Greenfield facility with 51,200 MTPA capacity is on track for commissioning in March 2026.
Phase 1 of the Dahej Battery Materials facility (25,000 MTPA) is scheduled for commissioning in early 2027.
Currently engaged with 34 global customers for battery-grade iron phosphate, with a 70% sample approval rate.
Upgraded existing facilities to add 5,000 tons of battery-grade iron phosphate capacity to serve commercial scale-up orders.
👀 What to Watch
Investors should monitor the timely commissioning of the Nandesari facility in March 2026 as it will drive the next phase of volume growth. The company's unique position as an ex-China supplier for battery materials makes it a high-potential play in the EV supply chain.
Sudeep Pharma Q3 FY26 PAT Surges 66% YoY; Groundbreaking for 25,000 MT Battery Chemicals Plant
Sudeep Pharma reported a robust Q3 FY26 with total income rising 52% YoY to ₹179.2 crore, driven by strong demand in specialty ingredients and pharma segments. Profit After Tax (PAT) surged 66% YoY to ₹47.7 crore, supported by healthy EBITDA margins of 37.3%. A major strategic highlight is the company's entry into the EV battery materials space with a new 25,000 MT plant in Dahej and the commencement of early commercial orders. The company is also on track to commission its Nandesari greenfield facility by Q4 FY26, further boosting capacity.
Key Highlights
Total Income grew 52% YoY to ₹179.2 Cr in Q3 FY26; 9M FY26 revenue reached ₹482.1 Cr.
EBITDA increased 60% YoY to ₹66.8 Cr with margins expanding to 37.3% from 35.4% YoY.
Groundbreaking of Dahej Battery Chemicals Plant (Phase I: 25,000 MT) targeting the LFP battery market with a total project cost of ₹300 Cr.
Successfully upgraded existing iron phosphate capacity to 5,000 MT for battery-grade materials and secured initial commercial orders.
Greenfield manufacturing facility at Nandesari is on track for commissioning by Q4 FY26.
👀 What to Watch
Investors should note the strong earnings momentum and the significant strategic pivot into the high-growth EV battery materials sector as a long-term catalyst. Monitor the execution timelines of the Dahej plant and the ramp-up of the new Nandesari facility for sustained growth.
Sudeep Pharma Q3 FY26 Net Profit Rises 30% YoY to ₹26.87 Crore; Revenue Up 8%
Sudeep Pharma reported a strong performance for Q3 FY26, with standalone net profit growing 30.2% year-on-year to ₹26.87 crore. Revenue from operations saw a steady increase of 8.1% to ₹90.28 crore, while total income was bolstered by a significant rise in other income to ₹9.44 crore. For the nine-month period ended December 2025, the company achieved a profit of ₹81.82 crore, a 30.7% increase compared to the previous year. The company, which listed in November 2025, still holds ₹75.81 crore of unutilized IPO proceeds in term deposits intended for future capital expenditure.
Key Highlights
Net Profit for Q3 FY26 increased by 30.2% YoY to ₹26.87 crore from ₹20.63 crore.
Revenue from operations grew 8.1% YoY to ₹90.28 crore in the December quarter.
9M FY26 profit stands at ₹81.82 crore, up significantly from ₹62.61 crore in 9M FY25.
Other income jumped to ₹9.44 crore in Q3 FY26 compared to ₹2.29 crore in the same quarter last year.
Unutilized IPO proceeds of ₹75.81 crore are currently held in bank term deposits for planned machinery procurement.
👀 What to Watch
The company shows robust profit growth and efficient cost management in its first results post-listing. Investors should monitor the timely deployment of IPO proceeds into machinery, which is the primary catalyst for future capacity expansion.
Sudeep Pharma Q3 PAT Jumps 30% YoY to ₹26.87 Cr; Revenue Up 8.1%
Sudeep Pharma Limited reported a strong performance for the quarter ended December 31, 2025, with Profit After Tax (PAT) rising 30.2% YoY to ₹26.87 crore. Revenue from operations grew by 8.1% YoY to ₹90.28 crore, while 9-month PAT reached ₹81.82 crore compared to ₹62.61 crore in the previous year. The company, which listed in November 2025, still holds ₹75.81 crore of its IPO proceeds in term deposits pending deployment for capital expenditure. Additionally, the board has appointed Sharp & Tannan Associate as the internal auditor for FY 2026-27.
Key Highlights
Net Profit increased by 30.2% YoY to ₹26.87 crore in Q3 FY26 from ₹20.63 crore in Q3 FY25.
Revenue from operations grew 8.1% YoY to ₹90.28 crore against ₹83.48 crore in the previous year's quarter.
9-month PAT stands at ₹81.82 crore, showing significant growth over the ₹62.61 crore reported for the same period last year.
Unutilized IPO proceeds of ₹75.81 crore are currently held in bank term deposits for future machinery procurement.
Earnings Per Share (EPS) for the quarter improved to ₹2.42 from ₹1.90 YoY.
👀 What to Watch
Investors should monitor the timely deployment of the remaining ₹75.81 crore IPO proceeds into production machinery, which will be the primary driver for future capacity expansion. The strong bottom-line growth post-listing is a positive signal for long-term holders.
Sudeep Pharma Subsidiary Acquires Land in Dahej for ₹20.97 Cr for Battery Materials Plant
Sudeep Pharma's wholly-owned subsidiary, Sudeep Advanced Materials Private Limited, has acquired leasehold land rights in GIDC Dahej, Gujarat, for ₹20.97 crore. The land, measuring approximately 80,980 square meters, was purchased from DCM Shriram Fine Chemicals Limited. This strategic acquisition is intended for setting up a commercial manufacturing facility for Battery Grade Precursor Materials, specifically Iron Phosphate. This move marks a significant expansion into the high-growth electric vehicle and energy storage supply chain.
Key Highlights
Acquisition of 80,980.19 square meters of leasehold land in GIDC Dahej, Gujarat
Total transaction value of ₹20,97,03,000 excluding transfer charges and duties
Land purchased from DCM Shriram Fine Chemicals Limited by a wholly-owned subsidiary
New facility to focus on manufacturing Battery Grade Precursor Materials like Iron Phosphate
Strategic diversification into the renewable energy and EV battery material sector
👀 What to Watch
Investors should view this as a positive long-term growth driver as the company enters the specialized battery materials market. Monitor future announcements regarding project timelines, capital expenditure for the plant, and potential off-take agreements.
Sudeep Pharma Q2 FY26: Specialty Segment Grows 32% CAGR; New Plant to Commission in Q4
Sudeep Pharma conducted its maiden earnings call post-listing, highlighting a robust 32% CAGR in its specialty ingredients vertical since 2021, which now accounts for 40% of total revenue. The company is on track to commission its fifth and largest manufacturing facility in Nandesari by Q4 FY26 to address rising demand in regulated pharma and infant nutrition markets. Management clarified that 50% of its US business is exempt from recent tariffs, with customers absorbing the remaining impact, ensuring no significant volume loss. The strategic 85% acquisition of Ireland-based NSS in May 2025 further strengthens its global footprint in the high-barrier infant and medical nutrition segments.
Key Highlights
Specialty ingredients vertical achieved a 32% CAGR since 2021, contributing 40% of H1 FY26 revenues.
Fifth greenfield manufacturing facility in Nandesari, Gujarat, expected to be commissioned in Q4 FY26.
Acquired 85% stake in Ireland-based Nutrition Supplies and Services (NSS) to accelerate entry into infant nutrition.
Management confirmed 50% of US business is exempt from tariffs, with the rest seeing costs absorbed by clients.
Expanding into the battery materials market through Sudeep Advanced Materials (SAM) for LFP battery components.
👀 What to Watch
Investors should monitor the successful commissioning and ramp-up of the Nandesari facility in Q4 FY26 as a key growth driver. The stock offers unique exposure to high-barrier pharmaceutical excipients and the emerging LFP battery material supply chain.
